As next generation gene and cell therapies enter the market, outcomes-based reimbursement is emerging as a critical tool to align pricing with demonstrated clinical benefit. However, manufacturers continue to face significant challenges, from defining meaningful outcome measures to navigating payer expectations and evolving policy frameworks. This workshop offers a focused, strategic deep dive into how innovators can design feasible outcomes-based reimbursement models that build payer confidence and support sustainable patient access.

This workshop will gather experts to discuss:

• Understanding the strategic role of outcomes-based reimbursement in enabling timely access to high-cost advanced therapies
• Strengthening the data foundations and evidence required to engage effectively with payers
• Defining outcomes that are measurable, clinically meaningful, and operationally feasible to track
• Exploring operational challenges related to data collection, durability assessment, and real-world evidence generation